KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSELEXIS’ USE OF TWITTER AND SOCIAL MEDIA
Selexis is a user of Twitter and maintains a corporate account using the screen names @SelexisSA and @Selexis.
Selexis recognizes the importance of social media, including Twitter, and new communication channels that enable Selexis to engage in interactive discussion with the Company’s stakeholders. As a biotechnology company, Selexis is committed to abiding by the legal, ethical, and regulatory standards applicable to the Company. By maintaining an active Twitter account, Selexis aims to responsibly interact with stakeholders.
DISCLAIMERS
Selexis may respond to questions and comments that are presented via Twitter when appropriate. Selexis may not be able to respond immediately to questions or comments, and responses, if any, may be limited in nature.
There may be questions and/or comments that Selexis can not address, including, but not limited to, questions that are related to non-public confidential information, proprietary information, financial matters, ongoing legal matters, regulatory issues, and other aspects of Selexis’s business. Selexis will not respond to rumors, personal attacks, foul language, disparaging comments, or topics that do not relate directly to Selexis.
Twitter accounts that Selexis follows or is followed by do not indicate an endorsement of the account owner or their products and services.
Selexis may provide links or references to external websites that are not controlled by Selexis as part of its Tweets. However, Selexis does not endorse or claim responsibility for the content of such websites. Any links or references to such external websites are provided merely as a convenience to the users of the Twitter platform.
Selexis reserves all rights that relate to the Selexis Twitter accounts (@SelexisSA and @Selexis), including, but not limited to, all rights to add, remove, or modify any content or material that is posted on the account; discontinue the account; accept or reject those who may wish to follow the account; and respond to, or refrain from responding to, any questions or comments that are addressed to the account.
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.